Verastem Q3 adjusted loss widens on increased R&D expenses
Overview
US biopharma firm's Q3 net product revenue more than doubled yr/yr to $24 mln
Adjusted loss per share for Q3 missed analyst expectations
Company completed $250 mln public offering in October to fund clinical development
Outlook
Verastem expects FDA decision on AVMAPKI FAKZYNJA CO-PACK Blister Pack by Feb 7, 2027
Company plans to open Phase 3 TARGET-D 301 trial in 1L mPDAC by year-end 2026
Verastem expects cash runway to extend into 1H 2028, funding pivotal Phase 3 studies
Result Drivers
STEADY PRODUCT DEMAND - Co said AVMAPKI FAKZYNJA CO-PACK revenue was driven by strong refill growth, though offset by fewer new patient starts due to seasonal headwinds, commercial team changes, and evolving off-label use patterns
INCREASED R&D SPENDING - Co attributed higher research and development expenses to increased costs for investigator fees, manufacturing, contract research organizations, and personnel, including stock-based compensation
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Adjusted Loss Per Share | Miss | $0.72 | $0.46 (10 Analysts) |
Q3 Net Loss | $74.72 mln | ||
Q3 Income from Operations | -$75.22 mln | ||
Q3 Operating Expenses | $99.24 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Verastem Inc is $18.00, about 82.7% above its November 4 closing price of $9.85
Reuters Recommended Reads
Nov 5 - Entrada Therapeutics Q3 net loss narrows as expenses fall
Nov 5 - Fate Therapeutics Q3 net loss narrows as expenses fall
Nov 5 - Dyne Therapeutics Q3 net loss widens on higher trial costs
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)